Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Total Inventories : $2.96 Mil (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Sonoma Pharmaceuticals Total Inventories?

Sonoma Pharmaceuticals's total inventories for the quarter that ended in Dec. 2023 was $2.96 Mil. Sonoma Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $2.73 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Sonoma Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.14.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Sonoma Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 148.68.

Inventory Turnover measures how fast the company turns over its inventory within a year. Sonoma Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.61.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Sonoma Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.87.

Sonoma Pharmaceuticals Total Inventories Historical Data

The historical data trend for Sonoma Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Total Inventories Chart

Sonoma Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Inventories

Get a 7-Day Free Trial

3.41

2.18

2.53

2.66

2.86

Sonoma Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															2.85	2.86	2.73	2.51	2.96

Sonoma Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Sonoma Pharmaceuticals (NAS:SNOA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Sonoma Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.406	+	0.75 * 2.876	+	0.5 * 2.955	-	7.926
-	0	-	0)	/	13.6843
=	-0.14

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sonoma Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	2.734	/	1.678	*	365 / 4
	=	148.68

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Sonoma Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	1.678	/	2.734
	=	0.61

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sonoma Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	2.734	/	3.138
	=	0.87

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Sonoma Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (NAS:SNOA) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

O8Z3:Germany

Address

5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301

Website

https://www.sonomapharma.com

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.

Executives

Chad Norman White	officer: Interim CFO	645 MOLLY LANE, SUITE 150, WOODSTOCK GA 30189
Jerome J Dvonch	officer: Chief Financial Officer	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Robert Grant Edwards	officer: Chief Financial Officer	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Poggetto John Dal	officer: Chief Financial Officer	1129 N. MCDOWELL BLVD, PETALUMA CA 94954
Amy Moss Trombly	officer: Interim CEO	1314 MAIN STREET, SUITE 102, LOUSIVILLE CO 80027
Frederick J Sandford	director, officer: CEO and Interim CFO	C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Philippe Weigerstorfer	director	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert E Miller	officer: Chief Financial Officer	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
James J Schutz	director, officer: Chief Operating Officer	1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Marc Umscheid	officer: Chief Strategy/Mkt Officer	OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert Allen Northey	officer: Exec. VP of Res & Devlpment	C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sharon Surrey Barbari	director	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Russell Joseph Harrison	director	OCULUS INNOVATIVE SCIENCES, INC., 1129 NORTH MCDOWELL BLVD., PETALUMA CA 94954
John Mclaughlin	director	OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sameer Harish	other: Officer of Subsidiary (1)	RUTHIGEN, INC., 1129 N. MCDOWELL BLVD, PETALUMA CA 94954